Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions.

[1]  A. Carlsson,et al.  Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease. , 1999, Neurology.

[2]  B. Långström,et al.  Effects of the substituted (S)-3-phenylpiperidine (−)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains , 1999, Neuropharmacology.

[3]  B. Långström,et al.  Effects of the substituted (S)‐3‐phenylpiperidine (−)‐OSU6162 on PET measurements in subhuman primates: Evidence for tone‐dependent normalization of striatal dopaminergic activity , 1998, Synapse.

[4]  B. Långström,et al.  Synthesis of [11C-methyl]-(-)-OSU6162, its regional brain distribution and some pharmacological effects of (-)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography. , 1997, Nuclear medicine and biology.

[5]  P. Andrén,et al.  (−)‐OSU 6162 inhibits levodopa‐induced dyskinesias in a monkey model of Parkinson's disease , 1997, Neuroreport.

[6]  Bengt Långström,et al.  Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease , 1997, Annals of neurology.

[7]  L. Bednarz,et al.  Persistent activation of the dopamine D1 receptor contributes to prolonged receptor desensitization: studies with A-77636. , 1996, The Journal of pharmacology and experimental therapeutics.

[8]  M. Starr.  Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson' disease , 1995, Synapse.

[9]  A. Carlsson,et al.  Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships. , 1994, Journal of medicinal chemistry.

[10]  P. Strange.  Multiple dopamine receptors: relevance for neurodegenerative disorders. , 1994, Biochemical Society transactions.

[11]  J. Kebabian,et al.  A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. , 1992, European journal of pharmacology.

[12]  S B Dunnett,et al.  Behavioural analysis of unilateral monoamine depletion in the marmoset. , 1992, Brain : a journal of neurology.

[13]  J. Kebabian,et al.  Rapid reversal of denervation supersensitivity of dopamine D1 receptors by l-dopa or a novel dopamine D1 receptor agonist, A68930. , 1991, European journal of pharmacology.

[14]  Z. Susel,et al.  Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[15]  M. Horstink,et al.  Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[16]  J G Nutt,et al.  Levodopa‐induced dyskinesia , 1990, Neurology.

[17]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[18]  B. Weiss,et al.  Selective down-regulation of D1 dopamine mediated rotational behavior in supersensitive mice , 1988, Neuropharmacology.

[19]  U. Ungerstedt,et al.  Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. , 1971, Acta physiologica Scandinavica. Supplementum.

[20]  C. Sonesson.  Arylpiperidine and arylpyrrolidine derivatives with potential antipsychotic efficacy : synthesis and quantitative structure-activity relationships , 1995 .

[21]  B. Gomez-Mancilla,et al.  DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. , 1995, Journal of neural transmission. Supplementum.

[22]  D. Sibley,et al.  Molecular biology of dopamine receptors. , 1992, Trends in pharmacological sciences.